Related Experiment Video
Updated: May 18, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug
Xiao-Yan Cai1, Jeff Thomas, Constance Cullen
1Department of Biologics Bioanalytical, Merck, 1011 Morris Avenue, NJ 07083, USA. xiao-yan.cai@merck.com
Bioanalysis
|September 28, 2012
Summary
Patent expiry spurs biosimilar development. Demonstrating biosimilarity, especially via challenging immunogenicity assays, is crucial for regulatory approval and market entry of these biologic alternatives.
Area of Science:
- Biotechnology
- Pharmacology
- Immunology
Background:
- Patent expirations for blockbuster biologic drugs create significant market opportunities for biosimilars.
- Biosimilar development hinges on demonstrating analytical and clinical similarity to the reference biologic product.
- Regulatory agencies mandate rigorous evaluation of immunogenicity for biosimilar approval.
Purpose of the Study:
- To review the challenges in developing and validating immunogenicity assays for biosimilar drug development.
- To discuss the difficulties in interpreting qualitative immunogenicity data for comparative studies.
- To highlight the critical role of immunogenicity assessment in biosimilar regulatory pathways.
Main Methods:
- Review of current regulatory guidelines for biosimilar immunogenicity testing.
- Analysis of common immunogenicity assay formats and their limitations.
- Discussion of strategies for data interpretation in comparative immunogenicity studies.
Main Results:
- Immunogenicity assays are often qualitative, posing significant challenges for demonstrating comparability.
- Validation of these assays requires careful consideration of sensitivity, specificity, and reproducibility.
- Interpreting subtle differences in immunogenicity data between biosimilar and originator products is complex.
Conclusions:
- Developing and validating robust immunogenicity assays is a critical hurdle in biosimilar development.
- Standardized approaches and advanced analytical techniques are needed to overcome data interpretation challenges.
- Successful biosimilar approval relies heavily on comprehensive immunogenicity assessment.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...